Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor

Trial Profile

A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Stem-cell-therapeutics-ExCellThera (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 12 Dec 2022 According to a ExCellThera media release, results from retrospective analysis comparing outcomes of patients treated with ECT-001 to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants were presented in an oral session during the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract #665).
    • 12 Dec 2022 Findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants published in the ExCellThera Media Release.
    • 04 Nov 2022 According to an ExCellThera media release, findings of a matched-controlled real-world analysis comparing outcomes of patients treated with ECT-001 in this trial to cord blood and matched unrelated donor peripheral blood stem cell transplants control cohorts identified from the CIBMTR (Center for International Blood and Marrow Transplant Research) research database has been accepted for oral presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top